Trade ACTU anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Actuate Therapeutics, Inc. (ACTU) is trading at US$1.70, up 0.30% today as of Aug 28, 10:16 EDT. The company has a market capitalisation of US$30.5M. Over the past 52 weeks, ACTU has traded between US$0.90 and US$9.22. On Syfe you can trade ACTU with $0 commission and add it to your watchlist.
| Previous close | US$1.69 |
|---|---|
| Market cap | US$30.5M |
| 52-week range | US$0.90 – US$9.22 |
| Volume | 363.41K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Year: 2024
Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma
Jun 9, 12:25 PM · MT Newswires
B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating
Apr 15, 1:27 PM · MT Newswires
Actuate Therapeutics, Inc. (ACTU) stock is trading at US$1.70, +0.30% from the previous close of US$1.69.
The market cap for Actuate Therapeutics, Inc. (ACTU) stock is approximately US$30.5M.
The 52-week high for Actuate Therapeutics, Inc. (ACTU) stock is US$9.22.
The 52-week low for Actuate Therapeutics, Inc. (ACTU) stock is US$0.90.
Actuate Therapeutics, Inc. (ACTU) does not currently pay a dividend.
Stay on top of ACTU
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
